pre-IPO PHARMA

COMPANY OVERVIEW

4DMT is a gene therapy company with a transformative discovery platform—Therapeutic Vector Evolution— that empowers us to invent optimized and proprietary AAV vectors, each specifically tailored for the treatment of a rare disease with a high unmet medical need.


LOCATION

  • Emeryville, CA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Musculoskeletal Disease
  • Ophthalmology
  • Rare Diseases
  • Respiratory Disease

  • WEBSITE

    https://www.4dmoleculartherapeutics.com


    CAREER WEBSITE

    https://www.4dmoleculartherapeutics.com/careers/


    SOCIAL MEDIA


    INVESTORS

    arrowmark-partners berkeley-catalyst-fund bvf-partners chiesi-ventures cure-duchenne janus-henderson-investors mirae-asset pappas perceptive-advisors pfizer-ventures ridgeback-capital-management viking-global-investors


    PRESS RELEASES


    Dec 2, 2020

    4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development


    Nov 18, 2020

    4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors


    Sep 8, 2020

    4D Molecular Therapeutics Appoints John F. Milligan, Ph.D., as Executive Chairman of Board of Directors


    Aug 27, 2020

    4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors


    Aug 19, 2020

    4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa


    For More Press Releases


    Google Analytics Alternative